Company / Current Liabilities
Spyre Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$58.7M
FY2025
5-year range
$14.7M / $58.7M
FY2021-FY2025
Trend
+8.6%
vs FY2024
Sector context
#133 of 213
Health Care
What the data says
At $59M, Spyre Therapeutics, Inc.'s current liabilities ranks #81 of 213 in the Health Care sector. Current Liabilities has increased for 3 consecutive years, from $15M in FY2022 to $59M in FY2025.
Based on SEC 10-K filings.
$59M in FY2025 with a 5-year CAGR of +29.0%.
Increased from $32M to $59M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +58.8%
- 5-Year CAGR
- +29.0%
- 10-Year CAGR
- -
Sector benchmark
#81 of 213 in Health CareTop 38% of 213This company $58.7M Sector average $1.6B
▼
-96.3% below sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +29.0%, indicating consistent growth.
- In FY2025, current liabilities increased 8.6% year-over-year.
- Ranks #133 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.7M | +8.6% |
| FY2024 | $54.1M | +69.1% |
| FY2023 | $32.0M | +118.2% |
| FY2022 | $14.7M | -27.2% |
| FY2021 | $20.1M | +22.5% |
| FY2020 | $16.4M | -10.4% |
| FY2019 | $18.4M | +79.3% |
| FY2018 | $10.2M | +81.9% |
| FY2017 | $5.6M | +42.0% |
| FY2016 | $4.0M | +57.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026